Eurogentec is an international company founded in 1985 and part of Kaneka Corp. since 2010. Headquartered in Liege (Belgium) it provides products and services to scientists involved in the life science research, molecular diagnostics and therapeutic developments. Eurogentec has production sites in Europe and United States of America. The company is recognized as one of the major suppliers in the field of genomics and proteomics as well as a trusted US FDA inspected Contract Development and Manufacturing Organization (CDMO) for the bio-production of pharmaceuticals (vaccines and medicines). | Founded in 1985 and part of Kaneka Corporation since 2010, Eurogentec is a leading biotechnology and CDMO company specializing in GMP-certified manufacturing of starting materials and APIs. With facilities in Europe and the USA, we support plasmid DNA, mRNA, recombinant proteins, peptides, antibody fragments, and therapeutic oligonucleotides from early research to clinical and commercial production. Our expertise in process development and scale-up ensures high-quality solutions at every stage. Detailed Description of Products (Event Specific) max 500 characters in English – Plasmid DNA : Starting material & APIs including Nano-plasmids & Minicircle DNA. FastTrack: 4-month production. – mRNA : IVT mRNA (0.1g–50g), saRNA, gRNA with co-/post-transcriptional modifications. – Proteins : GMP production in E. coli & P. pastoris for biotech & pharma. – Conjugates : Chemically modified recombinant proteins for clinical use. – Therapeutic Oligos : ASOs, siRNA, aptamers, CpG oligos. – Peptides : Linear, cyclic & complex-modified. – Antibody Fragments : scFv, Fab, VHH, bispecifics. | Eurogentec—part of Kaneka Corp. since 2010—is a leading international company founded in 1985 and headquartered in Belgium. Accredited by the Belgian AFMPS, US FDA, and Japanese MHLW, we deliver trusted solutions to the life sciences, molecular diagnostics, and therapeutic development sectors. As a major supplier in genomics (oligonucleotides, qPCR kits, reagents) and proteomics (custom and catalog antibodies, peptides), we also act as a reliable CDMO for process development and GMP manufacturing of vaccines and medicines—including therapeutic oligonucleotides, peptides, plasmids, recombinant proteins, mRNA and VHH antibodies. Our comprehensive services cover process transfer, development and optimization, scale-up, tox and clinical batches, GMP and GMP-like manufacturing, Quality Control, QA release, and ICH stability studies. From early-phase development to commercialization, Eurogentec is your single partner for every step of the journey.
EuBiologics
EuBiologics is listed biopharmaceutical company located in Korea, developing human vaccines against infectious disease using two proprietary technologies, EcML (Monophosphoryl Lipid A, TLR4 agonist) and recombinant CRM197 (Carrier protein). We have currently 7 vaccines in the pipeline. TCV (Typhoid Conjugate Vaccine, NDA), PCV (Pneumococcal Conjugate Vaccine, Ph I completed), MCV (Meningococcal Conjugate Vaccine, Ph I completed), HZV (Herpes Zoster Virus, Non-Clinical), RSV (Respiratory Syncytial Virus, Non-clinical), OCV (Oral Cholera Vaccine, commercialized) and EuCorVac-19 (COVID-19, Ph III). OCV have been supplied to UNICEF/PAHO and several more countries since 2016 after WHO-PQ and captured more than 90% of the public cholera vaccine market. EuBiologics can also offer advanced cGMP-level facilities providing fully integrated CRMO services for mammalian cell and microbial derived biopharmaceutical, from cell line development to large-scale commercial GMP production. EuBiologics is especially specialized in a variety of protein-based therapeutics and vaccines as we have had plenty of experience working with many innovative biotech in getting the right therapeutics. We possess extensive working knowledge of developing and manufacturing different types of vaccine. | EuBiologics is a publicly traded biopharmaceutical company specializing in human vaccines targeting infectious diseases. We leverage our proprietary adjuvant (TLR4 agonist, E. coli-derived) and recombinant carrier protein (CRM197), both of which have global IP protections, to develop novel vaccines. | x
EirGenix, Inc.
EirGenix is the leading company in biologics development and GMP manufacturing and has solid experience in various biologics (mAb, bi-specific mAbs, r-proteins, COVID-19 Spike protein, fusion proteins, RNA, ADC, Viral Vector, etc.). As of now, we have successfully completed more than 70 biologics projects for clients all over the world. Moreover, we have signed global licensing collaborations with Sandoz for our Trastuzumab biosimilar (EG12014), which BLA has been submitted to the US FDA in December 2021. Among others, our services include: – Up to 12×2,000L SUB mammalian cGMP production capacity – Dual cell Line development & banking for mammalian and microbial systems – Upstream/Downstream process development – Analytical and QC – One-stop full service from DS to DP – US FDA inspected and the EIR report received – Japan PMDA and Taiwan FDA certified – Biosimilars pipeline available for licensing and or collaboration | EirGenix is a leading CDMO in biologics development and GMP manufacturing that has solid experience in various biologics (mAb, BsAbs, r-proteins, COVID-19 Spike protein, fusion proteins, ADC, pDNA, Viral Vector, etc.). We have completed > 70 biologics projects for clients all over the world. Moreover, we have signed global licensing collaborations with Sandoz for our Trastuzumab biosimilar (EG12014), which BLA was approved in the EU and waiting for US FDA approval. Among others, our services include: – One-stop full service from DS to DP CGMP Clinical and Commercial manufacturing of Microbial and Mammalian strains – Up to 12 x 2,000L mammalian capacity – Dual Cell Line Development & banking for mammalian and microbial systems – Upstream/Downstream process development – Analytical and QC – US FDA, Japan PMDA, Australia TGA, EU EMA, and Taiwan FDA inspected – Biosimilars pipeline available for licensing and or collaboration | EirGenix is Taiwan’s leading biologics CDMO, providing end-to-end development and manufacturing solutions that meet FDA, PMDA, EMA, and TGA standards. Since 2012, we have successfully delivered 100+ projects across mammalian and microbial platforms, supporting global clients from early-stage development to commercialization. Our comprehensive services include cell line development, process and analytical development, and cGMP manufacturing for both clinical and commercial supply. With a robust 12 × 2,000L single-use bioreactor capacity and expanding microbial fermentation capabilities, we are equipped to handle large-scale production needs. Award-Winning Excellence Since 2017, EirGenix has been consistently recognized for excellence in biologics development and manufacturing, earning multiple prestigious industry awards that demonstrate our commitment to innovation and quality. Recent Awards (2023-2025): – Best ADC CDMO in Taiwan – Asia Pacific Biopharma Excellence Awards 2025 – Most Promising Monoclonal Antibodies Pipeline – Taiwan Biopharma Excellence Awards (TBEA) 2024 – National Science and Technology Drug R&D Award – Gold Medal (2023, Taiwan) (for EirGasun® 150mg) – BioProcessing Excellence Award – Greater China Region (2022) (IMAPAC Asia Biologics – Manufacturing Conference) Accelerate your biologics development with EirGenix. Visit us at BIO 2025 or contact us to explore tailored solutions for your next project.
Ecolab Life Sciences
Ecolab’s Purolite™ Resins receive continued investment from Ecolab to support development, production, and customer support. We have one of the industry’s largest technically trained sales teams in ion exchange and specialty resin technology, backed by five Research and Development centers, nine application labs and five production facilities. With our ability to quickly respond, supply, and develop, we can solve your application challenges and optimize your system. Ecolab’s Life Sciences division is dedicated to developing the best possible products and services to support our customers in the pharmaceutical industry. Our comprehensive solutions and technical expertise are focused on cleaning, sanitization and contamination control, all while ensuring safety, compliance and operational efficiency. Our strategy is to stay focused on two core areas: Global Trends and Regulatory Changes that impact your operations, and develop solutions to keep you on the cutting edge. | Ecolab Life Sciences is a segment of Ecolab and a global leader in technologies and services designed to enhance productivity, reduce costs, and accelerate the development of critical medicines. Leveraging over a century of innovation, Ecolab Life Sciences provides comprehensive solutions and expert guidance across bio-decontamination, drug purification, active pharmaceutical ingredients (APIs) and excipients. With a strong commitment to ensuring safety, compliance, and operational efficiency, Ecolab Life Sciences partners with organizations to support their mission of advancing health and wellbeing worldwide.
Cytovance Biologics
Cytovance Biologics, Inc. (Cytovance Biologics) is a leading biopharmaceutical contract development and manufacturing organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule active pharmaceutical ingredients (APIs). Cytovance Biologics utilizes both mammalian cell culture and microbial fermentation to express monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines, and other biological products, including plasmid DNA and cell-based therapeutics. In addition to its clinical and commercial CGMP API manufacturing services, Cytovance Biologics offers well-integrated development services supporting the entire product lifecycle, including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization. Our state-of-the-art facilities in Oklahoma City are designed to meet United States, European Union, and other global regulatory standards. Cytovance Biologics offers deep industry expertise and unique customized services for the scale-up and CGMP manufacture of protein-based therapeutics; from early-stage pre-clinical development to commercial production, for both mammalian and microbial. Further information can be found at www.cytovance.com. | Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) offering ingenuity and integrated development services to support large molecule biologics throughout the journey from R&D to regulatory approval. These services include mammalian cell line development, cell banking, microbial strain development, process and analytical development, process characterization, and cGMP manufacturing. The company’s 140,000+ sq. ft. state-of-the-art facilities in America’s Heartland are designed to meet US, EU, and global regulatory requirements. Find out more at https://cytovance.com/ | Streamline your biomanufacturing with a US-based partner that is large enough to support you at every stage but small enough to stay agile and provide your program with the care it deserves. Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) offering ingenuity and integrated development services to support large molecule biologics throughout the journey from R&D to regulatory approval and commercial supply. These services include mammalian cell line development, cell banking, microbial strain development, process and analytical development, process characterization, and cGMP manufacturing. The company’s 140,000+ sq. ft. state-of-the-art facilities in America’s Heartland are designed to meet US, EU, and global regulatory requirements.
Cytiva
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery. We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more. | Diagnostic assays like the ones you’re developing are in demand. Set yourself up for success by choosing a supplier that delivers quality products for your entire workflow and offers specialized services and capabilities needed to commercialize your assays. Using a single supplier for multiple components, from membranes to magnetic beads, can streamline your development process and ultimately accelerate the commercialization of diagnostic assays and kits. Cytiva can help you speed up and scale up without staffing up! With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical knowledge and talent, a broad and deep portfolio, and exceptional service to support biotechs at every stage from discovery to delivery. Visit cytiva.com/diagnostics to learn more. | Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. | Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in 43 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
Coriolis Pharma Research GmbH
Coriolis Pharma is a global contract research organization and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines. The company’s offerings include liquid and lyophilized freeze-dried drug formulation development from early stage to market approval and beyond, lyophilization freeze-drying process development, and analytical development under R&D and GMP. Non-GMP manufacturing services for a wide range of products complete the service offering. More than 725 clients – from start-ups to big pharma – already rely on Coriolis’s scientific expertise. For each project, our highly skilled scientists develop customized study designs that align with our customers’ drug development strategies. | Coriolis Pharma is a globally operating contract research and development organization (CRDO) and a leader in formulation research and development of biopharmaceutical drugs, including cell and gene therapy products and vaccines. We provide high-quality services for liquid and lyophilized drug products from early stage to commercialization and beyond. Manufacturing support and contract analytical services under R&D and GMP complete our service portfolio. Coriolis was founded in 2008 and currently employs more than 200 employees from over 36 nations around the world. | Coriolis Pharma is a globally operating, science‑driven contract research and development organization (CRDO) specializing in drug product development, formulation, lyophilization technologies, and advanced analytics for biopharmaceuticals. Founded in 2008 and with laboraties in Europe and the U.S., the company supports clients from early development to commercialization, offering both R&D and GMP-compliant analytical services across a broad range of biological modalities. As a premier partner for biopharmaceutical innovation, Coriolis Pharma provides expertise in developing liquid and lyophilized drug products, optimizing stability for proteins, peptides, nucleic acids, vaccines, gene and cell therapy products, and virus(-like) particles up to biosafety level S2. Its interdisciplinary team, supported by an expert scientific advisory board, delivers cutting‑edge, tailor-made solutions designed to accelerate and de-risk drug development programs throughout the entire product lifecycle. Coriolis Pharma’s service portfolio includes comprehensive analytical method development, qualification, and validation, ensuring robust regulatory support for biopharmaceutical pipelines. Its commitment to scientific excellence, innovation, and independent operation makes the company a trusted partner for biotechnology firms and pharmaceutical developers worldwide. Meet Coriolis Pharma at the BIO Convention to learn how their integrated development, analytical, and manufacturing services can help advance your biotherapeutic programs faster, safer, and more efficiently.
Corealis Pharma Inc.
COREALIS Pharma is a private company offering formulation development and clinical supplies manufacturing services to pharmaceutical and biotech companies. Our state-of-the-art laboratories and manufacturing facilities allow our experts to successfully complete the most complex formulation development and clinical supply manufacturing mandates. COREALIS Pharma’s goal is to provide complete satisfaction to all clients by providing high-quality services and delivering compliant phase-appropriate drug products on time, every time. Formulation Development – COREALIS Pharma offers “turn-key projects”, ie performing the complete project development steps of a finished product. We can also take on specific projects and perform one or several phases of the product development process. We have a very flexible approach and pride ourselves in providing superior personalized services with fast project start-up. Clinical Suply Manufacturing – COREALIS Pharma offers clinical dosage manufacturing, release and stability testing, and packaging for clinical trials. Support during the submission to regulatory agencies and transfer of the products and processes to a large scale manufacturing site are also provided. All clinical manufacturing work is performed within COREALIS’s quality systems which are reviewed on a regular basis by Qualified Quality Persons. | COREALIS Pharma is a private company offering formulation development and clinical supplies manufacturing services to pharmaceutical and biotech companies. Our state-of-the-art laboratories and manufacturing facilities allow our experts to successfully complete the most complex formulation development and clinical supply manufacturing mandates. COREALIS Pharma’s goal is to provide complete satisfaction to all clients by providing high-quality services and delivering compliant phase-appropriate drug products on time, every time. | Corealis Pharma is a private company offering formulation development and clinical supplies manufacturing services to biotech and pharma. While our scientific and executive leadership has not changed since 2005, our capabilities are constantly evolving. Our state-of-the-art facilities allow our experts to complete the most complex formulation development and clinical supply manufacturing mandates for OSD products. We’re dedicated to providing complete satisfaction by ensuring high-quality services and delivering compliant, phase-appropriate formulation development and clinical supply on time, every time. | . | description/summary Corealis Pharma is a premier CDMO company, specializing in oral solid dosage (OSD) formulation development and phase I, II and early Phase III clinical supply manufacturing for trials worldwide. Located in Laval (Greater Montreal), Quebec, Canada, the state-of-the-art facilities, spanning over 60,000 sq ft, boasts modern technological solutions specializing in oral solid dosage (OSD) formulations. Specifically, Corealis provides: Pre-formulation & Solubility Enhancement: API characterization, solubility screening, and compatibility studies to set a solid foundation. Advanced Formulation Strategies: Spray drying, hot melt extrusion (HME), lipid-based systems, and particle engineering for stable, scalable products. Bioavailability Enhancement Technologies: Cutting-edge approaches to improve absorption, including cyclodextrin complexes and supersaturating formulations.
Cincinnati Children’s Hospital Medical Center
Cincinnati Children’s Innovation Ventures as well as staff from Cincinnati Children’s Applied Gene and Cell Therapy Center will be onsite.